Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CareRA: Treatment Strategies for Early Rheumatoid Arthritis
NCT01172639Phase 4Completed
- Start
- Feb 2009
- Primary completion
- Jun 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methotrexate, prednisone, 5-aminosalicylic acid + sulphasalazine and leflunomide in rheumatoid arthritis (RA) (5 arms). Primary endpoint: Remission According to DAS28-CRP at 104 weeks. Started Feb 2009; status: completed.
02
Drugs
methotrexateprednisone5-aminosalicylic acid + sulphasalazineleflunomide
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01172639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01172639.